GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
It also secures US $ 10 million for US launch and commercialization
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
Data to establish the safety profile and human dose of vaccine candidate
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Subscribe To Our Newsletter & Stay Updated
